Most Read Articles
Pearl Toh, 7 days ago
Mepolizumab added on to standard of care for patients with severe eosinophilic asthma better improves health-related quality of life (HRQOL), along with improved asthma symptoms and lung function compared with placebo, according to the MUSCA* study.
Pearl Toh, 6 days ago
Treatment with abiraterone acetate and prednisone for metastatic prostate cancer (mPC) in patients who responded poorly to initial androgen-deprivation therapy (ADT) showed encouraging results with favourable overall survival (OS) to historical controls, although the prespecified criteria for a positive result was not met , according to the S1014* trial.
5 days ago
Blood pressure (BP) ≥140/90 mm Hg appears to increase the risk of maternal complications and adverse foetal outcomes, irrespective of the number of medications used, a study suggests. However, the greatest risk is observed among pregnant women taking multiple agents and whose BP levels are within the aforementioned range.
7 days ago
Relapse after randomization is more likely to occur in patients with severe baseline hallucinations, reports a new study. In addition, the presence of baseline hallucinations is associated with a greater risk of relapse after discontinuation of risperidone vs continued risperidone treatment.

TAVR comparable to SAVR in real-world intermediate-risk patients

Pearl Toh
one month ago
Dr Matthew Brennan
Transcatheter aortic valve replacement (TAVR) is an effective and safe alternative to surgical aortic valve replacement (SAVR) for intermediate- and high-risk patients in the real world, with no significant difference in stroke and mortality rates at 1 year, and discharge to home being more common among TAVR patients, according to the ADVICE* study presented at the recent ACC.17 Scientific Session held in Washington, DC, US.    

Although previous randomized clinical trials (RCTs) have shown TAVR to be safe and effective in intermediate- and high-risk patients with aortic stenosis, the real-world GARY** trial showed a higher 1-year mortality rate among intermediate-risk patients who received TAVR than SAVR. This raised questions regarding how generalizable are RCT results of TAVR to the real world and to different patient subgroups with different risk profiles, according to Dr Matthew Brennan of Duke University Medical Center in Durham, North Carolina, US.

The current real-world observational ADVICE study included 9,464 propensity-matched patients (median age 82 years, 48 percent female) at intermediate or high risk for surgery (STS PROM*** ≥3 percent) in the TVT# Registry and STS## Database who underwent TAVR or SAVR in the US. [ACC.17, abstract 408-08]

Compared with SAVR, TAVR patients were more commonly being discharged home (70 percent vs 41 percent; p<0.01), which according to Brennan, “reflects a less demanding early recovery [among TAVR patients].”

In-hospital mortality rate was lower (3 percent vs 5 percent; p<0.001) and postoperative length of stay in hospital was shorter (4 vs 8 days; p<0.001) among patients who received TAVR compared with SAVR. On the other hand, new pacemaker implantation (12.8 percent vs 6.3 percent; p<0.001) and in-hospital major vascular complication (4.2 percent vs 0.4 percent; p<0.001) were higher with TAVR, while in-hospital stroke incidence was similar between the TAVR and SAVR groups (2.5 percent vs 2.7 percent; p=0.4), which Brennan said were consistent with results from previous clinical trials.      

At 1 year postprocedure, rates of death (hazard ratio [HR], 0.93; p=0.18) and stroke (HR, 1.18; p=0.13) were similar between the two groups, with the data from subgroup analysis (including age, gender, previous cardiac surgery, prior stroke, and chronic lung disease) being consistent with the overall comparative findings for each clinical outcome.

Subanalyses indicate that patients with prior cardiac surgery or chronic lung disease might benefit more from TAVR than SAVR, observed Brennan.  

Both the TAVR and SAVR groups also had similar ‘days alive and out of hospital (DAOH)’, with the majority of patients in both groups spending <1 month in an acute care hospital within the first year after treatment. In addition, similar DAOH between the two groups was observed even when patients were stratified by STS PROM score (≥3 and <5, ≥3 and <8, ≥8).

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 7 days ago
Mepolizumab added on to standard of care for patients with severe eosinophilic asthma better improves health-related quality of life (HRQOL), along with improved asthma symptoms and lung function compared with placebo, according to the MUSCA* study.
Pearl Toh, 6 days ago
Treatment with abiraterone acetate and prednisone for metastatic prostate cancer (mPC) in patients who responded poorly to initial androgen-deprivation therapy (ADT) showed encouraging results with favourable overall survival (OS) to historical controls, although the prespecified criteria for a positive result was not met , according to the S1014* trial.
5 days ago
Blood pressure (BP) ≥140/90 mm Hg appears to increase the risk of maternal complications and adverse foetal outcomes, irrespective of the number of medications used, a study suggests. However, the greatest risk is observed among pregnant women taking multiple agents and whose BP levels are within the aforementioned range.
7 days ago
Relapse after randomization is more likely to occur in patients with severe baseline hallucinations, reports a new study. In addition, the presence of baseline hallucinations is associated with a greater risk of relapse after discontinuation of risperidone vs continued risperidone treatment.